AAPLLoadingMSFTLoadingNVDALoadingGOOGLLoadingAMZNLoadingMETALoadingTSLALoadingAMDLoadingNFLXLoadingCOINLoadingPYPLLoadingSPYLoadingQQQLoadingIWMLoadingJPMLoadingVLoadingDISLoadingKOLoadingJNJLoadingNKELoadingXOMLoadingASMLLoading
FreeXBI3 min read

Equal-weighted biotech is a bet on the financing window

The index last traded at 144.37, -3.60% on the session. I usually write about individual readouts. This is about the tide under all of them, which moves the equal-weighted index more than any single result.

XBI
Delayed

Why the weighting changes the question

A cap-weighted biotech index is dominated by large companies with revenue. An equal-weighted one is dominated by numbers: many smaller companies, most without a product on the market, each funding its research by selling shares.

That makes the equal-weighted index a measure of how easily those companies can raise money. When the window is open they fund trials, pipelines advance, and the index rises on progress. When it closes they cut programmes or sell themselves cheaply, whatever the science says.

What the window depends on

  • Interest rates, since a company with no earnings for years is a very long duration asset
  • Follow-on offerings and their pricing, which is the window measured directly
  • Acquisitions by large pharmaceutical companies, which recycle capital back into the sector
  • Generalist fund flows, which arrive late in a recovery and leave early in a downturn

In early-stage biotech, the science decides which companies win. The financing window decides how many get to find out.

Why I am flat

The window opens and shuts on its own schedule, and I have no reliable way to call the next change. I would rather track it than guess at it, and let the readouts I write about carry the specific views.

What would change my mind

Follow-on offerings pricing at premiums rather than discounts, alongside a steady run of acquisitions. That combination says capital is chasing the sector rather than the other way round.

The author holds no position in the instruments discussed. Opinion. Not advice. Not a financial promotion approved under FSMA s.21. Quote data is delayed. Past performance is not a reliable indicator of future results.

Comments

0 comments
Sign in to comment.

No comments yet

Be the first to weigh in.